Status
Conditions
Treatments
About
This is a prospective, observational cohort study to establish the minimal residual disease (MRD) model for predicting relapse risk and identifying disease recurrence in patients with colorectal adenocarcinoma based on the miRNA platform.
Blood miRNA markers will be evaluated. The study will enroll approximately 600 participants, including participants with malignancies or benign diseases, and healthy participants.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Inclusion Criteria for the colorectal cancer arm:
1.18-75 years old 2. Pathologically confirmed as colorectal adenocarcinoma 3. Medically able to receive radical surgery for colorectal cancer 4. Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 to 1 5. Ability to provide a written informed consent
Inclusion Criteria for the healthy control arm:
1.18-75 years old 2. No clinically significant finding based on routine blood tests, urinalysis, CT, and ultrasound examinations 3. Ability to provide a written informed consent
Inclusion Criteria for the intestinal polyp arm:
1.18-75 years old 2. Pathologically confirmed as colorectal adenoma 3. Ability to provide a written informed consent
Exclusion criteria
600 participants in 3 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal